-
6 days ago | 
interventionalnews.com | Eva Malpass
“At the publication of this public census, we’ve opened Pandora’s box and we’re going to have to make a change,” Pavan Najran (The Christie Hospital NHS Foundation Trust, Manchester, UK) said at a recent meeting, referencing a UK-wide survey looking at the use of medical devices that contain animal derivatives. Touted as the first and largest study of its kind, Najran underlined the poignancy of the results set against increasing patient autonomy, religious diversity in the UK and consent.
-
1 week ago | 
interventionalnews.com | Eva Malpass
Merit Medical Systems has announced that it has acquired Biolife Delaware in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife manufactures patented haemostatic devices under the brand names StatSeal and WoundSeal. A press release made by Merit states that the aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately US$120 million.
-
1 week ago | 
interventionalnews.com | Eva Malpass
New findings from the COVER-ALL trial suggest that software-based assessment of the minimal ablative margin during percutaneous thermal ablation significantly improves treatment precision and may reduce local tumour progression in liver cancer patients.
-
1 week ago | 
interventionalnews.com | Eva Malpass
Histotripsy is a non-thermal, non-ionising and non-invasive focused ultrasound technique which relies on cavitation for mechanical tissue breakdown at the focal point. Leading research into the novel technique, Mishal Mendiratta-Lala (University of Michigan, West Bloomfield, USA)—principal investigator for the #HOPE4LIVER trial evaluating histotripsy in liver tumours— provides a deep dive into histotripsy, discussing its application and evolution in the near future.
-
2 weeks ago | 
venousnews.com | Eva Malpass
Envveno Medical has today announced that its manuscript titled, ‘Three-year outcomes of surgical implantation of a novel bioprosthetic valve for the treatment of deep venous reflux’,has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the femoral vein of 11patients with active or healed venous ulcers (CEAP classifications C5–C6).
-
2 weeks ago | 
venousnews.com | Eva Malpass
Imperative Care today announced the completion of patient enrolment in its SYMPHONY-PE study, a pivotal investigational device exemption (IDE) trial evaluating the safety and efficacy of the company’s Symphony thrombectomy system for the treatment of acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, the study was conducted at 19 leading interventional radiology, interventional cardiology and vascular surgery centres across the USA.
-
2 weeks ago | 
vascularnews.com | Eva Malpass
Imperative Care today announced the completion of patient enrolment in its SYMPHONY-PE study, a pivotal investigational device exemption (IDE) trial evaluating the safety and efficacy of the company’s Symphony thrombectomy system for the treatment of acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, the study was conducted at 19 leading interventional radiology, interventional cardiology and vascular surgery centres across the USA.
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
Imperative Care today announced the completion of patient enrolment in its SYMPHONY-PE study, a pivotal investigational device exemption (IDE) trial evaluating the safety and efficacy of the company’s Symphony thrombectomy system for the treatment of acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, the study was conducted at 19 leading interventional radiology, interventional cardiology and vascular surgery centres across the USA.
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
A keynote session on the future of interventional oncology (IO) brought artificial intelligence (AI) to the forefront of discussion, highlighting both its potential and the ethical, legal, and regulatory challenges it presents.
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
“Although [real-world registries] seem unsexy, it’s the direction of travel,” said David Breen (Southampton University Hospitals, Southampton, UK), describing the comparative advantages and challenges of randomised controlled trials (RCTs) and real-world registries in providing kidney tumour ablation data. “Let’s talk honestly about RCTs. There are problems,” began Breen, during his talk at the European Conference on Interventional Oncology (ECIO; 12–16 April, Rotterdam, The Netherlands).
